Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells

Oncology Reports

Volumn 17, Issue 5, 2007, Pages 1269-1273

  Nagayama, Yuji ^a   Hase, Wataru ^a   Motoyoshi, Yasuhide ^a   Saitoh, Ohki ^a   Sogawa, Rintaroh ^a   Nakao, Kazuhiko ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Cyclophosphamide; Effector T cells; GITRL; PC61

Indexed keywords

CD4 ANTIGEN; CYCLOPHOSPHAMIDE; INTERLEUKIN 2 RECEPTOR ALPHA; TNFSF18 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL; ARTICLE; C3H MOUSE; FEMALE; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LIVER TUMOR; METHODOLOGY; MOUSE; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD4; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; FEMALE; GENETIC VECTORS; IMMUNOTHERAPY; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TRANSFECTION; TUMOR NECROSIS FACTORS;

EID: 34548567391     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.5.1269     Document Type: Article

References (25)

1. Houghton AN and Guevara-Patino JA: Immune recognition of self in immunity against cancer. J Clin Invest 114: 468-471, 2004. (Pubitemid 39572095)
2. Danke NA, Koelle DM, Yee C, Beheray S and Kwok WW: Autoreactive T cells in healthy individuals. J Immunol 172: 5967-5972, 2004. (Pubitemid 38621196)
3. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6: 345-352, 2005.
4. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163: 5211-5218, 1999.
5. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T and Nakayama E: Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res 59: 3128-3133, 1999. (Pubitemid 29316012)
6. + regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 25: 207-217, 2002.
7. + regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2: 1, 2002.
8. + regulatory cells uncovers immune responses to shared murine tumor rejection. Eur J Immunol 32: 3267-3275, 2002.
9. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194: 823-832, 2001.
10. Motoyoshi Y, Kaminoda K, Saitoh O, Hamasaki K, Nakao K, Ishii N, Nagayama Y and Eguchi K: Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep 16: 141-146, 2006.
11. Shevach EM and Stephens GL: The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity? Nat Rev Immunol 6: 613-618, 2006. (Pubitemid 44134094)
12. Ronchetti S, Zollo O, Bruscoli S, Agostini M, Bianchiri R, Nocentini G, Ayroldi E and Riccadi C: GITR, a member of the TNF receptor superfamily is costimulatory to mouse T lymphocyte subpopulations. Eur J Immunol 34: 613-622, 2004. (Pubitemid 39255908)
13. + regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3: 135-142, 2002.
14. + immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16: 311-323, 2002.
15. + T cells. J Immunol 172: 7306-7314, 2004.
16. Stephens GL, McHugh RS, Whitters MJ, Young DA, Luxenberg D, Carreno BM, Collins M and Shevach EM: Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol 173: 5008-5020, 2004. (Pubitemid 39387783)
17. Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, Terwey TH, Kochman AA, Lu S, Miles RC, Sakaguchi S, Houghton AN and van den Brink MRM: Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol 176: 6434-6442, 2006. (Pubitemid 43787825)
18. - T cells responsible for in vivo protective immunity. BIKEN J 30: 1-8, 1987.
19. Calmels B, Paul S, Futin N, Ledoux C, Stoeckel F and Acres B: Bypassing tumor-associated immune suppression with recombinant adenovirus expressing membrane bound or secreted GITR-L. Cancer Gene Ther 12: 198-205, 2005. (Pubitemid 40205100)
20. Mizuguchi H, Koizumi N, Hosono T, Utoguchi N, Watanabe Y, Kay MA and Hayakawa T: A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther 8: 730-735, 2001. (Pubitemid 32496435)
21. Nagayama Y, Nishihara E, Namba H, Yokoi H, Hasegawa M, Mizuguchi H, Hayakawa T, Yamashita S and Niwa M: Targeting the replication of adenovirus to p53-defective thyroid carcinoma with a p53-regulated Cre-loxP system. Cancer Gene Ther 8: 36-44, 2001. (Pubitemid 32151895)
22. + regulatory T cells. J Exp Med 202: 885-891, 2005.
23. + T-cell responses and tumor immunity. Cancer Res 66: 4902-4912, 2006.
24. Hiura T, Kagamu H, Miura S, Ishida A, Tanaka H, Tanaka J, Gejyo F and Yoshizawa H: Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. J Immunol 175: 5058-5066, 2005. (Pubitemid 41456389)
25. + T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci USA 100: 10902-10906, 2003.